The U.S. Food and Drug Administration granted approval to Seattle Genetics Inc.’s Tukysa tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Gilead Sciences Inc. announced that the company will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. CDC.
Gilead Sciences Inc. announced that the company is providing $17.6 million in grants to 30 organizations in the United States through the Gilead HIV Age Positively initiative.
Three leading health and pharmaceutical companies – GlaxoSmithKline, Teva, Takeda – and EcoVadis, the leading provider of sustainability risk and performance ratings for global supply chains, announced the launch of the Responsible Health Initiative.
Klick Health’s growing commercialization partner portfolio is proud of the successful exit of Circulation, one of Klick’s first incubation initiatives.
Novartis announced a five-year commitment in the fight against malaria. The Swiss-based company will invest more than $100 million to advance research and the development of “next-generation treatments” to combat emerging resistance to artemisinin and other currently used antimalarials.
The goal of “Forever Welcome” is to help ensure that the United States is a safe place for immigrants to pursue their dreams.